Anfarm

Executive Summary

Anfarm is a privately-held generic pharmaceutical company headquartered in Athens, Greece, with over four decades of industry experience since its founding in 1975. The company has established a robust global footprint through a diversified strategy encompassing licensing, exports, and third-party manufacturing, enabling it to supply products across Europe, Canada, Africa, and emerging markets including MENA, LATAM, and APAC. As a mature player in the generic drug space, Anfarm leverages its long-standing relationships and regulatory expertise to navigate complex international markets. The company's business model emphasizes low-capital-intensity expansion via partnerships, allowing it to commercialize a broad portfolio without extensive internal manufacturing infrastructure. While specific financial metrics and pipeline details are not publicly disclosed due to its private status, Anfarm's sustained operations across multiple geographies suggest a stable revenue base and ability to adapt to evolving generic market dynamics. The company's stage classification as "Approved" indicates that it has already gained at least initial regulatory clearances for its products, positioning it for continued incremental growth through geographic expansion and new product launches. However, the lack of detailed financial transparency and exposure to competitive pricing pressures in generics warrant a cautious outlook. Overall, Anfarm represents a resilient, established generic drug manufacturer with a proven international reach, but limited visibility into near-term growth drivers.

Upcoming Catalysts (preview)

• Q3 2026New Market Entry in LATAM via Licensing Agreement70% success
• Q1 2027FDA Approval for a High-Value Generic Product50% success
• Q4 2026Strategic Partnership for API Supply Chain Expansion60% success